International Journal of Research and Review
Vol. 10; Issue: 12; December 2023
Website: www.ijrrjournal.com
Review Article *E-ISSN: 2349-9788; P-ISSN: 2454-2237*

Exploiting BRAF Mutation for Treatment of Malignant Melanoma: A Literature Review

Vanesya Rizky Chendriadi[1], Willy Sandhika[2]

[1]Medical Study Program, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia
[2]Department of Anatomic Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia

Corresponding author: Willy Sandhika

DOI : https://doi.org/10.52403/ijrr.20231285

ABSTRACT

Malignant melanoma, a deadly type of skin cancer, presents considerable challenges in clinical management. However, the advent of targeted therapies capitalizing on BRAF mutations has ushered in a new era of optimism for treating melanomas. This investigation delves into the utilization of BRAF mutations as a focused approach in addressing malignant melanoma. Anomalously activated RAS-RAF-MEK-ERK signaling, particularly through the prevalent V600E mutation, instigates uncontrolled cell proliferation and survival in melanocytes. Melanoma arises de novo from melanocytes carrying genetic alterations, with RAF mutations being the most common. Mutated RAF genes, notably the V600E mutation, induce dysregulated cell cycle progression, fueling unchecked proliferation. Given that RAF is a pivotal component of the RAS-MAPK pathway, manipulating this pathway emerges as a promising strategy to impede cancer growth. However, not all melanoma cases exhibit RAS mutations, necessitating molecular testing to identify BRAF mutations before initiating targeted therapy. Detecting typically somatic BRAF mutations mandates melanoma tissue as a specimen. The presence of V600E BRAF mutations becomes a crucial factor for employing BRAF inhibitor therapy. This review article underscores the imperative nature of RAF mutation testing in melanoma patients, serving as a predictive tool to determine the cancer's responsiveness to RAF inhibitor treatment. The identification of BRAF mutations offers a targeted therapeutic avenue, instilling fresh hope for personalized and effective interventions in the management of malignant melanoma.

Keywords: skin cancer; melanoma; braf mutation

INTRODUCTION

Malignant melanoma, an aggressive and potentially fatal type of skin cancer, poses a formidable challenge in the field of oncology due to its resistance to conventional treatment approaches like surgery, radiotherapy, and chemotherapy.[1] The pressing need for more efficacious interventions has spurred the development of innovative therapeutic strategies. In this quest, the recognition of BRAF mutations, specifically the prevalent V600E mutation, has introduced a renewed sense of optimism for addressing malignant melanoma. The onset of melanoma stems from the de novo transformation of melanocytes, the cells responsible for pigment production, marked by genetic mutations. Among these mutations, alterations in the RAF gene, notably the V600E mutation, play a pivotal role in driving dysregulated cell cycle progression and uncontrolled cellular proliferation—hallmark features of the aggressive nature of cancer. [2]

RAF stands as a pivotal gene in the RAS-MAPK signaling pathway, governing fundamental cellular processes crucial for growth, survival, and differentiation. The disruptive influence of the V600E BRAF mutation on this regulatory balance

perpetuates signaling, fostering the uncontrolled proliferation of melanoma cells.[3] The RAF pathway emerges as a promising avenue for suppressing cancer growth, with BRAF inhibitors like vemurafenib and dabrafenib representing a transformative shift in melanoma therapeutics. These inhibitors precisely target the aberrantly activated BRAF protein, disrupting the signaling cascade and impeding the unrestrained growth characteristic of BRAF-mutant melanomas.[4] This paradigm shift from broad-spectrum treatments to precision medicine holds the potential for more effective, personalized interventions attuned to the molecular intricacies of individual tumors.

Nevertheless, the clinical application of BRAF inhibitors poses challenges. Their efficacy hinges on the presence of the specific V600E mutation, which is not universally present in all melanoma cases. Recognizing the role of RAS mutations becomes crucial in gauging therapeutic responsiveness.[5] This acknowledgment underscores the inherent heterogeneity of melanomas, prompting a transition from standardized approaches to a more sophisticated, molecularly guided strategy. To fully harness the potential of BRAF inhibitors and navigate melanoma heterogeneity, molecular assays designed to detect BRAF mutations become indispensable. These assays, reliant on melanoma tissue as the primary specimen, provide insights into the genetic landscape of individual tumors.[6] Consequently, they serve as vital tools in the therapeutic decision-making process, empowering clinicians to determine whether a specific melanoma possesses the necessary mutations for BRAF inhibitor responsiveness.

Moreover, melanoma's notorious resistance to conventional chemotherapy and radiotherapy presents a formidable challenge. Traditional chemotherapeutic agents and radiation treatments encounter limitations when applied to melanoma, given their inadequacy in combating the cancer's aggressive and intricate nature. Additionally, melanoma cells can develop resistance to standard treatments, diminishing their responsiveness. Consequently, alternative therapeutic modalities, such as immunotherapy and targeted medications, have garnered significance in melanoma treatment. These approaches seek to leverage the body's immune system or specifically target molecular abnormalities like BRAF mutations, offering a precise treatment option for patients. [7]

As the curtain rises on a more profound exploration of BRAF mutations in malignant melanoma, this study aspires to conduct a comprehensive analysis of the multifaceted landscape of these genetic alterations. From the transformative potential of targeted therapies to the nuanced challenges posed by melanoma heterogeneity, this investigation underscores the pivotal role of understanding and exploiting BRAF mutations. Through this study, it is anticipated that, in addition to unraveling the molecular intricacies of this challenging illness, a pathway will be paved for more effective and tailored treatment techniques, ultimately leading to improved outcomes for patients worldwide.

LITERATURE REVIEW

2.1 Introduction to Melanoma and BRAF Mutation

Melanoma, a type of skin cancer originating from the malignant transformation of melanocytes—pigment-producing cells responsible for skin colour—is predominantly located in the epidermis, the outermost skin layer. Renowned for its potential to metastasize and spread to other organs, melanoma poses a life-threatening risk. Various risk factors contribute to its development, with excessive exposure to ultraviolet (UV) radiation from the sun or tanning beds being a prominent contributor. Individuals with fair skin, light-coloured eyes, and a history of blistering sunburns face an elevated risk. Family history of

melanoma or specific genetic mutations, such as those in the BRAF gene, further heighten susceptibility. Clinical presentation often involves the appearance of atypical moles or changes in existing ones. The ABCDE rule—Asymmetry, irregular Borders, uneven Colour, a Diameter larger than 6 millimetres, and Evolution over time—serves as a guideline for identifying potential melanoma signs. Early detection is crucial for successful treatment. [8]

BRAF mutations significantly contribute to melanoma's emergence. This gene provides instructions for a protein involved in a signalling pathway regulating cell growth. Mutations, particularly the V600E mutation, abnormally activate the pathway, fostering uncontrolled cell proliferation and contributing to melanoma formation. About half of all melanomas harbour BRAF mutations, especially prevalent in superficial spreading melanomas, a common subtype. [6] Identifying BRAF mutations not only enhances our understanding of melanoma's underlying biology but has also become pivotal for personalized treatment strategies.

The development of targeted therapies, exemplified by BRAF inhibitors like vemurafenib and dabrafenib, as well as MEK inhibitors such as trametinib, signifies a significant stride in addressing mutated BRAF proteins and their downstream signaling pathways. These drugs have demonstrated remarkable efficacy in the treatment of advanced melanomas carrying BRAF mutations, resulting in improved patient outcomes. The pivotal role of BRAF mutations in the molecular landscape of melanoma not only provides valuable insights for diagnosis but also lays the foundation for effective treatment strategies. [4] The advent of targeted therapies tailored for BRAF-mutated melanomas represents a noteworthy breakthrough, highlighting the essential role of personalized medicine in melanoma management.

It is noteworthy that BRAF mutations in melanoma are non-heritable somatic alterations, manifesting within the body's cells and not transmitted across generations. Moreover, not all melanoma patients exhibit BRAF mutations, underscoring the molecular heterogeneity inherent in the disease. The absence of universally present BRAF mutations emphasizes the importance of considering diverse genetic and molecular factors contributing to melanoma development. This recognition guides the formulation of personalized treatment approaches based on the distinct molecular characteristics exhibited by individual tumors. [9]

2.2 Understanding the BRAF Gene

Situated on chromosome 7, the BRAF gene encodes instructions for the synthesis of the BRAF protein, a pivotal player in cell signaling pathways governing cell growth and division. As an integral component of the RAS-RAF-MEK-ERK pathway, this signaling cascade facilitates the transmission of external signals from the cell membrane to the nucleus.[10] The pathway's significance lies in its regulation of essential cellular processes, including proliferation, differentiation, and survival. Upon binding of external signals, such as growth factors, to cell surface receptors, activation of the RAS-RAF-MEK-ERK pathway ensues. In its normal state, the BRAF protein functions as a kinase, orchestrating the addition of phosphate groups to other proteins within the signaling pathway. This phosphorylation process activates downstream components, ultimately controlling gene expression and cellular behavior. The precise functioning of the BRAF gene is imperative for maintaining controlled cell growth and averting uncontrolled proliferation.[11]

However, mutations in the BRAF gene, particularly the V600E mutation, can disturb this delicate equilibrium. The V600E mutation results in a persistently activated BRAF protein, incessantly signaling for cell division even without external stimuli. This dysregulation can contribute to the onset of various cancers, including melanoma. Recognizing the normal function of the

BRAF gene is crucial, not only for elucidating its role in cellular processes but also for devising targeted therapies that specifically address the repercussions of BRAF mutations.[3] By targeting the mutated BRAF protein in conditions like melanoma, researchers and clinicians aspire to restore balance to cell signaling and impede the uncontrolled growth characteristic of cancer cells.

Mutations in the BRAF gene, frequently encountered in cancer, can manifest spontaneously during DNA processes, UV radiation exposure, exposure to carcinogenic agents, inherited mutations (which elevate risk but do not ensure cancer), age-related accumulation of mutations, and error-prone DNA replication. However, not all BRAF mutations signify malignancy. While certain BRAF mutations are commonly linked to various cancers, not every BRAF mutation leads to malignancy. Some BRAF mutations may be benign or possess uncertain clinical significance.[11] The specific type and location of the BRAF mutation, along with its context within the cellular environment, play a pivotal role in determining whether it contributes to cancer development. Molecular testing and thorough analysis are often imperative to characterize the nature and potential impact of a specific BRAF mutation. It's crucial to note that the mere presence of a BRAF mutation does not guarantee malignancy, and additional factors, such as the overall genetic profile of the tumor and the patient's clinical history, are taken into account when assessing the risk and progression of cancer.[11]

The assessment of BRAF mutations, particularly in the context of melanoma, involves employing molecular testing methods to analyze tumor tissue. The predominant approach is BRAF mutation testing, wherein specific mutations in the BRAF gene, particularly the common V600E mutation, are identified. Techniques such as polymerase chain reactions (PCR) or next-generation sequencing (NGS) are commonly utilized due to their sensitivity and specificity. Additionally, immunohistochemistry (IHC) can be employed to evaluate the presence of the mutated BRAF protein in tissue samples, acting as a preliminary screening tool.[12] These tests are indispensable for individuals with melanoma, as the results guide treatment decisions, especially in the consideration of targeted therapies like BRAF inhibitors.

2.3 The Process of Proliferation

The inhibition of cell proliferation can be achieved through the use of anti-BRAF agents. In melanoma, the intricate regulation of cell proliferation is closely associated with the activity of the BRAF gene, which encodes the BRAF protein participating in cellular signaling pathways. The MAPK/ERK pathway holds a pivotal role in governing cell growth, differentiation, and survival. However, mutations, such as the prevalent V600E mutation, in the BRAF gene lead to the constitutive activation of the BRAF protein. This activated BRAF protein persistently signals downstream in the MAPK/ERK pathway, continuously transmitting growth signals to the cell nucleus. Consequently, melanoma cells undergo uncontrolled and aberrant cell proliferation. This rapid and unregulated cell division contributes to the initiation and advancement of melanoma tumors. Anti-BRAF agents, exemplified by vemurafenib and dabrafenib, are specifically designed to target and inhibit the activity of mutated BRAF proteins. By doing so, these inhibitors disrupt the hyperactive signaling in the MAPK/ERK pathway, effectively interrupting the uncontrolled cell proliferation characteristic of melanoma. The inhibition of BRAF interrupts the transmission of signals that propel the cell cycle, preventing melanoma cells from incessantly dividing and multiplying. Essentially, the administration of anti-BRAF drugs interferes with the molecular processes sustaining the unrestrained growth of melanoma cells. This targeted therapy signifies a significant leap forward in

melanoma treatment, addressing the underlying genetic abnormalities fueling the disease directly. Anti-BRAF agents aid in restoring a level of control over cell proliferation, slowing down or even halting the progression of melanoma tumors. While anti-BRAF medications can be effective, resistance may develop over time, prompting ongoing research into combination therapies and alternative treatment options to enhance efficacy. Additionally, the BRAF gene produces a crucial protein, namely the BRAF protein, that plays a vital role in cellular signaling pathways regulating cell growth and division. Mutations in the BRAF gene, including the V600E mutation, can result in the synthesis of a mutated BRAF protein with altered activity, contributing to the onset of melanoma. [13]

The identification of mutated BRAF protein can serve as an indication of mutations in the BRAF gene. Alterations in the DNA sequence of the BRAF gene can lead to modifications in the corresponding BRAF protein. Diagnostic techniques such as immunohistochemistry or molecular testing can be employed to identify and detect the presence of specific mutated proteins, providing insights into the genetic abnormalities propelling melanoma. However, while the presence of mutated BRAF protein suggests a mutated gene, additional genetic testing may be necessary for comprehensive analysis. [14]

In the context of melanoma, discovering a mutation in the BRAF protein strongly suggests the presence of mutations in the BRAF gene. The DNA within the BRAF gene acts as the template for generating the BRAF protein. Mutations in the gene can lead to the production of an altered protein, like the V600E mutated BRAF protein often linked to melanoma. Consequently, detecting a mutated BRAF protein is a robust indicator of potential simultaneous mutations in the BRAF gene, though direct genetic testing may be necessary to verify and delineate the specific mutations involved. [5]

2.4 Linking BRAF Mutations to Cancer Progression

BRAF mutations, particularly the V600E variant, play a crucial role in the intricate process of melanoma development and progression. The typical function of the BRAF gene involves regulating cell growth through the RAS-RAF-MEK-ERK signaling pathway.[3] However, when a mutation occurs, the BRAF protein undergoes constant activation, leading to continuous signaling along this pathway. This abnormal activation fosters uncontrolled cell proliferation, surpassing the usual mechanisms that regulate cell growth and division. The mutated BRAF protein enhances the division of melanocytes, the pigment-producing cells in the skin, contributing to the formation of tumors. Significantly, BRAF mutations are frequently identified in dysplastic nevi, precursors to melanoma. The sustained activation of the signaling pathway due to BRAF mutations facilitates the transformation of these atypical moles into invasive melanoma, characterized by uncontrolled growth and the potential to invade surrounding tissues. Moreover, BRAF-mutated melanomas demonstrate an increased ability to metastasize, spreading to distant organs. [12]

In RAS-RAF-mutated melanoma, cell proliferation is driven by the abnormal activation of the RAS-RAF-MEK-ERK signaling pathway. The mutated RAS protein, often a result of genetic alterations, initiates a series of events leading to continuous activation of the RAF protein, particularly BRAF in many cases. This persistent signaling activates downstream components, including MEK and ERK, resulting in the activation of genes promoting cell growth and division. Unlike normal cells, where this pathway is tightly regulated, mutations in RAS and RAF genes lead to sustained activation, propelling uncontrolled cell proliferation—a hallmark of cancer. The continuous stimulation of this signaling cascade overrides the usual cellular checkpoints that govern the cell

cycle, enabling melanoma cells to rapidly replicate. [15]

BRAF mutations linked to melanoma are typically acquired during an individual's lifetime and are not commonly inherited. These mutations often result from exposure to environmental factors, such as ultraviolet (UV) radiation or other carcinogenic substances. Alternatively, they may occur spontaneously during cellular processes like DNA replication and repair. While most BRAF mutations in cancer are acquired, there are rare instances where individuals may inherit specific genetic conditions that predispose them to developing certain types of cancers, including those involving BRAF mutations. However, the inherited mutations alone do not guarantee the development of cancer and are influenced by additional genetic and environmental factors. [16]

The mutated BRAF protein drives uncontrolled cell proliferation by persistently activating the RAS-RAF-MEK-ERK signaling pathway, fueling tumor growth.[3] Cancer cells with BRAF mutations resist apoptosis, enhancing survival and promoting invasion into surrounding tissues. These mutations are crucial in the transformation of benign dysplastic nevi into malignant melanomas.[12] Understanding these effects is crucial for developing targeted therapies like BRAF inhibitors, which aim to disrupt aberrant signaling and impede the uncontrolled growth, survival, and invasive tendencies associated with BRAF-mutated cancer cells. Furthermore, somatic mutations play a significant role in the development of various conditions, including cancer. Cancer often arises from the accumulation of somatic mutations in certain genes that control cell growth and division. These mutations can lead to uncontrolled cell proliferation and the formation of tumors. Not everyone has somatic mutations because these changes are random events that occur throughout life. Unlike germline mutations, which can be inherited and affect all cells in an individual's body, somatic mutations are specific to certain tissues or cells. Therefore, the presence of a somatic mutation in one individual does not necessarily mean it will be present in all cells of the body or in the next generation.

2.5 Targeted Therapies for BRAF-Mutant Melanoma

Targeted treatments for BRAF-mutant melanoma have greatly advanced the therapeutic options for individuals with this specific genetic anomaly. The predominant BRAF mutation in melanoma, V600E, has prompted the development of several targeted therapies tailored to this mutation. BRAF inhibitors, such as vemurafenib and dabrafenib [4], function by obstructing the abnormal activity of the mutated BRAF protein, disrupting the RAS-RAF-MEK-ERK signaling pathway, and inhibiting the proliferation of cancer cells. It's noteworthy that BRAF inhibitors are frequently employed in conjunction with MEK inhibitors, like trametinib, to address potential resistance mechanisms and augment treatment effectiveness. [17]

The approach to treating melanoma with RAF mutations revolves around harnessing these targeted therapies, given the close association between RAF mutation status and the efficacy of BRAF inhibitors.[18] These therapies specifically target the mutated BRAF protein, aiming to hinder the uncontrolled growth and survival of cancer cells linked to BRAF mutations.[3] This dual inhibition strategy seeks to amplify the impact of targeted therapies, offering a more comprehensive approach to managing BRAF-mutant melanoma and enhancing patient outcomes.

Targeted therapies hold the promise of being effective and safe drugs for selectively eliminating cancer cells. These therapies are designed based on mutations detected in cancer cells. Unlike normal cells, cancer cells possess gene mutations that can be exploited as vulnerabilities for selectively eliminating cancer cells. For instance, the discovery of Homologous Recombinant Deficiency mutations in

ovarian cancer has introduced a new strategy for treating ovarian cancer with PARP-inhibitor therapy.[19] The identification of NTRK-gene fusion in head and neck cancer indicates a therapeutic response to NTRK-inhibitor therapy.[20]

2.6 The Importance of BRAF Mutation Check in Patient with Melanoma Cancer

Assessing BRAF mutations is crucial because the presence of a BRAF mutation provides an opportunity for a potential cure through the administration of anti-BRAF agents. In the absence of a BRAF mutation, melanoma cannot be effectively cured. The examination of BRAF mutations in melanoma holds significant importance due to the central role played by the BRAF gene in regulating fundamental cellular processes, particularly cell growth and division. Melanoma, a highly aggressive form of skin cancer, is frequently linked to mutations in the BRAF gene, specifically the V600E mutation. This particular mutation leads to the constant activation of the BRAF protein, activating the MAPK/ERK signaling pathway, which is crucial in controlling cell proliferation.[21]

The sequence of events triggered by the mutated BRAF results in uncontrolled and abnormal cell cycle progression. The heightened activity of the MAPK/ERK pathway continuously fosters the proliferation of melanoma cells, significantly contributing to the initiation, progression, and metastasis of melanoma tumors. Therefore, comprehending the nature and prevalence of BRAF mutations is not only essential for understanding the molecular foundations of melanoma but also for identifying potential therapeutic targets.[21]

The introduction of targeted therapies, particularly anti-BRAF agents, has transformed the landscape of melanoma treatment. These agents, designed to inhibit the abnormal activity of mutated BRAF, aim to disrupt the oncogenic signaling cascades that drive melanoma growth. These inhibitors effectively curtail the MAPK/ERK pathway by specifically targeting BRAF, resulting in the halt of cell cycle progression. The automatic interruption of cell cycle events, especially during the proliferation phase, holds promise in restraining the unrestrained growth of melanoma cells. BRAF mutations in melanoma, essentially, represent a strategic necessity in the development of precision treatment for melanoma patients. Identifying specific BRAF mutations guides the selection of targeted therapies tailored to the molecular profile of individual tumors. The inhibition of mutated BRAF using anti-BRAF agents signifies a paradigm shift in cancer treatment, offering a more precise and less indiscriminate approach compared to conventional chemotherapy. Moreover, this targeted therapeutic strategy not only holds potential in arresting cell cycle progression but also shows promise in mitigating the emergence of drug-resistant phenotypes commonly associated with traditional chemotherapeutic agents. Consequently, the examination of BRAF mutations in melanoma not only unveils the complexities of the disease's molecular landscape but also sets the stage for the development of more effective and personalized treatment modalities, ultimately enhancing outcomes for melanoma patients.[22]

2.7 Future Directions and Research Opportunities

The prospective direction of research in the realm of BRAF mutations and melanoma presents promising avenues for advancing our comprehension and approaches to treatment. Firstly, a critical aspect will involve delving into the mechanisms of resistance to BRAF inhibitors to improve the longevity of treatment responses. The identification and targeting of these resistance mechanisms have the potential to yield more effective and enduring therapeutic results. Additionally, an essential focus will be on exploring the diversity within BRAF-mutant melanomas and understanding how distinct genetic

profiles influence responses to treatment. Gaining deeper insights into the molecular complexities of BRAF-mutant melanomas may uncover novel therapeutic targets and biomarkers, contributing to enhanced patient stratification. The collaborative efforts between researchers and clinicians will play a pivotal role in translating these findings into innovative and tailored therapeutic interventions, ultimately shaping the future landscape of melanoma treatment.

CONCLUSION

In conclusion, while melanoma remains a formidable and potentially deadly disease, the discovery of BRAF mutations has opened a pathway of hope for improved treatment outcomes. The development of targeted therapies, particularly BRAF inhibitors, has revolutionized the management of BRAF-mutant melanomas, offering more effective and tailored treatment options. The importance of BRAF mutation testing cannot be overstated; it serves as a critical tool for oncologists in identifying the specific genetic alterations driving the cancer. This information guides the selection of targeted therapies, such as vemurafenib and dabrafenib, leading to more precise and personalized treatment approaches. As research in this field continues to advance, uncovering mechanisms of resistance, exploring combination therapies, and understanding the heterogeneity within BRAF-mutant melanomas are pivotal for enhancing long-term treatment success.

Declaration by Authors

Ethical Approval: Not Required
Acknowledgement: None
Source of Funding: None
Conflict of Interest: The authors declare no conflict of interest.

REFERENCES

1. Rosen C, Mayes T, Overholt C, Lucke-Wold B. Treatment of Melanoma Metastasis: Surgical, Chemotherapy, and Innovation. Med Discov. 2023 ;2(4):1032. DOI : http://dx.doi.org/10.52768/2993-1142/1032
2. Damsky WE, Bosenberg M. Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene. 2017 Oct 19;36(42):5771-5792. DOI: http://dx.doi.org/10.1038/onc.2017.189
3. Degirmenci U, Wang M, Hu J. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Cells. 2020 Jan 13;9(1):198. DOI: http://dx.doi.org/10.3390/cells9010198
4. Zhang W. BRAF inhibitors: the current and the future. Curr Opin Pharmacol. 2015 Aug; 23:68-73. DOI: http://dx.doi.org/10.1016/j.coph.2015.05.015
5. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012 Jul 9; 10:85. DOI: http://dx.doi.org/10.1186/1479-5876-10-85
6. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018 Jan;31(1):24-38. DOI: http://dx.doi.org/10.1038/modpathol.2017.104
7. Kalal BS, Upadhya D, Pai VR. Chemotherapy Resistance Mechanisms in Advanced Skin Cancer. Oncol Rev. 2017 Mar 24;11(1):326. DOI: https://doi.org/10.4081%2Foncol.2017.326
8. Duarte AF, Sousa-Pinto B, Azevedo LF, Barros AM, Puig S, Malvehy J, Haneke E, Correia O. Clinical ABCDE rule for early melanoma detection. Eur J Dermatol. 2021 Dec 1;31(6):771-778. DOI: https://doi.org/10.1684/ejd.2021.4171
9. Castellani G, Buccarelli M, Arasi MB, Rossi S, Pisanu ME, Bellenghi M, Lintas C, Tabolacci C. BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Cancers (Basel). 2023 Aug 8;15(16):4026. DOI: https://doi.org/10.3390/cancers15164026
10. Paja Fano M, Ugalde Olano A, Fuertes Thomas E, Oleaga Alday A. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid

carcinoma. Evaluation against real-time polymerase chain reaction. Endocrinol Diabetes Nutr. 2017 Feb;64(2):75-81. English, Spanish. DOI: https://doi.org/10.1016/j.endinu.2016.12.004

11. Śmiech M, Leszczyński P, Kono H, Wardell C, Taniguchi H. Emerging *BRAF* Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks. Genes (Basel). 2020 Nov 12;11(11):1342. DOI: https://doi.org/10.3390/genes11111342
12. Saroufim M, Novy M, Taraif S, Habib RH, Loya A, Rauscher B, Kriegshäuser G, Oberkanins C, Khalifeh I. BRAF mutational epidemiology in dysplastic nevi: does different solar UV radiation exposure matter? J Eur Acad Dermatol Venereol. 2014 May;28(5):615-25. DOI: https://doi.org/10.1111/jdv.12148
13. Wang AX, Qi XY. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. IUBMB Life. 2013 Sep;65(9):748-58. DOI: https://doi.org/10.1002/iub.1193
14. Jasek K, Buzalkova V, Minarik G, Stanclova A, Szepe P, Plank L, Lasabova Z. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors. Virchows Arch. 2017 Jan;470(1):29-36. DOI: 10.1007/s00428-016-2044-4
15. Ottaviano M, Giunta EF, Tortora M, Curvietto M, Attademo L, Bosso D, Cardalesi C, Rosanova M, De Placido P, Pietroluongo E, Riccio V, Mucci B, Parola S, Vitale MG, Palmieri G, Daniele B, Simeone E, On Behalf Of Scito Youth. BRAF Gene and Melanoma: Back to the Future. Int J Mol Sci. 2021 Mar 27;22(7):3474. DOI: https://doi.org/10.3390/ijms22073474
16. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012 Jun 1;26(11):1131-55. DOI: https://doi.org/10.1101%2Fgad.191999.112
17. Griffin M, Scotto D, Josephs DH, Mele S, Crescioli S, Bax HJ, Pellizzari G, Wynne MD, Nakamura M, Hoffmann RM, Ilieva KM, Cheung A, Spicer JF, Papa S, Lacy KE, Karagiannis SN. BRAF inhibitors: resistance and the promise of combination treatments for melanoma. Oncotarget. 2017 Aug 3;8(44):78174-78192. DOI: http://dx.doi.org/10.18632/oncotarget.19836
18. Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC. Targeted Therapy in Advanced Melanoma with Rare *BRAF* Mutations. J Clin Oncol. 2019 Nov 20;37(33):3142-3151. DOI: https://doi.org/10.1200/jco.19.00489
19. Cintantya DT, Sandhika W. Genetic Mutation Assay in Ovarian Cancel Patient. International Journal of Scientific Advances. 2023 July; 4(4). DOI: 10.51542/ijscia. v4i4.22
20. Prayogo HE, Sandhika W. NTRK-fusion detection in thyroid and salivary gland cancer offers a targeted therapy with NTRK-inhibitor. GSC Biological and Pharmaceutical Sciences. 2023 October 25(01), 131-137. DOI: https://doi.org/10.30574/gscbps.2023.25.1.0416
21. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018 Jan;31(1):24-38. DOI: 10.1038/modpathol.2017.104.
22. Liu Y, Sheikh MS. Melanoma: Molecular Pathogenesis and Therapeutic Management. Mol Cell Pharmacol. 2014;6(3):228. DOI: http://dx.doi.org/10.4255/mcpharmacol.14.03

How to cite this article: Vanesya Rizky Chendriadi, Willy Sandhika. Exploiting BRAF mutation for treatment of malignant melanoma: a literature review. *International Journal of Research and Review*. 2023; 10(12): 845-853. DOI: *https://doi.org/10.52403/ijrr.20231285*

******